Actuate 1801 Part 3B (elraglusib)
A randomised phase 2 found that adding the GSK-3 inhibitor elraglusib to standard chemotherapy lengthened survival in metastatic pancreatic cancer; a phase 3 is needed to confirm it.
Overview
Part 3B of the Actuate 1801 study randomised patients with previously untreated metastatic pancreatic ductal adenocarcinoma to gemcitabine and nab-paclitaxel with or without elraglusib. The company reported improved overall survival and one-year survival with elraglusib. As a phase 2 result it is hypothesis-generating, and Actuate has said a confirmatory phase 3 is planned.
Similar pages
not linked directly; found by shared links- CompanyActuate Therapeutics
- TrialStudy to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Adv
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialSaltikva for Metastatic Pancreatic Cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialTRYbeCA-1
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialLAPIS
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialPANOVA-3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- TrialNAPOLI 3
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.
- Key paperMPACT (Von Hoff 2013): nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer
Shares Gemcitabine + nab-paclitaxel, Pancreatic ductal adenocarcinoma.